Wall Street Analysts Are Neutral on Top Healthcare Picks

Analysts fell to the sidelines weighing in on Day One Biopharmaceuticals (DAWN – Research Report) and InnovAge Holding (INNV – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Day One Biopharmaceuticals (DAWN)
Oppenheimer analyst Matthew Biegler maintained a Hold rating on Day One Biopharmaceuticals today. The company's shares closed last Tuesday at $6.99.
According to TipRanks.com, Biegler has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -13.8% and a 28.1% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Zentalis Pharmaceuticals, and Arvinas Holding Company.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Day One Biopharmaceuticals with a $33.75 average price target.
InnovAge Holding (INNV)
William Blair analyst Ryan Daniels maintained a Hold rating on InnovAge Holding today. The company's shares closed last Tuesday at $2.85.
According to TipRanks.com, Daniels is a 4-star analyst with an average return of 7.7% and a 49.6% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Lifestance Health Group, and Pediatrix Medical Group.
InnovAge Holding has an analyst consensus of Hold.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

11 hours ago

• Business Insider

Dassault Systemes price target lowered to EUR 27 from EUR 28 at Jefferies

Jefferies lowered the firm's price target on Dassault Systemes (DASTY) to EUR 27 from EUR 28 and keeps an Underperform rating on the shares. The firm says ongoing macro uncertainty means positive surprises are unlikely in the company's Q2. It believes questions over whether Dassault will meet guidance are persist until year-end. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Business Insider

12 hours ago

• Business Insider

Sarepta price target lowered to $30 from $84 at JPMorgan

JPMorgan lowered the firm's price target on Sarepta (SRPT) to $30 from $84 and keeps an Overweight rating on the shares. The firm made changes to its revenue assumptions for key Elevidys post the disclosure of second non-ambulatory patient death. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Business Insider

12 hours ago

• Business Insider

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

JPMorgan analyst Anupam Rama lowered the firm's price target on Sage Therapeutics (SAGE) to $8.50 from $11 and keeps a Neutral rating on the shares. The firm cites the acquisition deal price by Supernus Pharmaceuticals for the target cut. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>